Ozanimod for treating moderately to severely active ulcerative colitis

Equality Impact Assessment (Guidance development) (PDF 155 KB)

Final draft guidance

Final appraisal document (PDF 200 KB)

Committee papers (PDF 4.71 MB)

Public committee slides (PDF 1.58 MB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 312 KB)

Final scope (PDF 210 KB)

Equality impact assessment (Scoping) (PDF 136 KB)

Final stakeholder list (PDF 178 KB)

Draft scope post referral (PDF 204 KB)

Draft matrix post referral (PDF 178 KB)